Home

AbbVie (ABBV)

184.60
-0.98 (-0.53%)
NYSE · Last Trade: May 10th, 11:13 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close185.58
Open185.75
Bid184.61
Ask185.09
Day's Range184.23 - 189.77
52 Week Range153.58 - 218.66
Volume7,806,410
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield6.560 (3.55%)
1 Month Average Volume8,651,653

Chart

About AbbVie (ABBV)

AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More

News & Press Releases

2 High-Yield Dividend Stocks to Buy in May and Hold Foreverfool.com
Via The Motley Fool · May 10, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · May 9, 2025
Recent Report Shows That Rep. Jefferson Shreve Bought Up to $4.75M Worth of Apple Stockbenzinga.com
Via Benzinga · May 9, 2025
Thursday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · May 8, 2025
Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks
Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season.
Via StockStory · May 7, 2025
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Boughtbenzinga.com
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags.
Via Benzinga · May 7, 2025
This House of Representative Just Bought Up To $915K In AbbVie Stockbenzinga.com
Via Benzinga · May 7, 2025
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concernsbenzinga.com
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks
Via Benzinga · May 6, 2025
1 Mega-Cap Stock Worth Your Attention and 2 to Keep Off Your Radar
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.
Via StockStory · May 6, 2025
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?benzinga.com
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.
Via Benzinga · May 5, 2025
Here Are All the Dividend Kings Beating the S&P 500 in 2025 -- and the 2 That Are the Best Stocks to Buy Nowfool.com
Via The Motley Fool · May 5, 2025
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?fool.com
Via The Motley Fool · May 4, 2025
Invest in These ETFs to Prepare Your Portfolio for a Recessionfool.com
Being prepared is important
Via The Motley Fool · May 3, 2025
Benzinga Bulls And Bears: Lilly, Microsoft, Starbucks — And Markets Fully Recover Tariff Chaos Lossesbenzinga.com
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · May 3, 2025
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.
Via MarketBeat · May 2, 2025
8 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · May 1, 2025
Netflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades'benzinga.com
Via Benzinga · April 30, 2025
AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritisbenzinga.com
AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales increase in Q1.
Via Benzinga · April 29, 2025
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Yearsbenzinga.com
Via Benzinga · April 29, 2025
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next?benzinga.com
Shares of AbbVie (ABBV) have gained more than 12% in the past week. But now they are overbought and may reverse.
Via Benzinga · April 29, 2025
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Weekbenzinga.com
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this week.
Via Benzinga · April 29, 2025
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.
Via StockStory · April 29, 2025
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loomtalkmarkets.com
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.
Via Talk Markets · April 28, 2025
Why AbbVie Stock Trounced the Market Todayfool.com
Via The Motley Fool · April 28, 2025
These S&P500 stocks are moving in today's sessionchartmill.com
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · April 28, 2025